Cellectis S.A. (CLLS)
CLLSNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$1.11
-0.0100 (-0.89%) today
At the close, Nov 10, 4:00 PM ET. After hours $1.11 –
- Market cap
- $111.59m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- $1.10 to $1.17
- 52-week range
- $0.8808 to $5.45
- Average volume
- 125.3k
- Previous close
- $1.12
Analysts
4 coveringHold1 buy, 2 hold, 1 sell
Targets a year out average $4.10, +269.4% from here
Earnings
Next report Nov 13, 2026
Financials
| Quarter | Dec 2012 |
|---|---|
| Revenue | $21.60m |
| Gross profit | $21.60m |
| Operating income | -$26.02m |
| Net income | -$31.06m |
News
8 latest- Cellectis S.A. Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026Fintel · Oct 28, 2026
- Cellectis' .HEAL-101 Lowers Triglycerides In Preclinical Study; Phase 1 Data Expected In H2'27 RTTNews · Oct 28, 2026
- Cellectis Unveils In Vivo Gene-Editing Plans for Severe Lipid DisordersMarketBeat · Oct 1, 2026
- Cellectis Posts Q2 2026 Results, Highlights Progress Across Allogenic CAR-T Pipeline RTTNews · Aug 7, 2026
- Barclays Initiates Coverage of Cellectis S.A. - Depositary Receipt (CLLS) with Overweight RecommendationFintel · May 28, 2026
- Clear Street Initiates Coverage of Cellectis S.A. - Depositary Receipt (CLLS) with Buy RecommendationFintel · Dec 23, 2025
- CITIZENS Maintains Cellectis S.A. - Depositary Receipt (CLLS) Outperform RecommendationFintel · Dec 16, 2025
- JEFFERIES Maintains Cellectis S.A. - Depositary Receipt (CLLS) Buy RecommendationFintel · Dec 16, 2025
The company
Cellectis is a genome engineering company developing genetic medicines for diseases that today demand a lifetime of treatment. Leveraging decades of expertise in programmable DNA-binding proteins, the Company has built a differentiated genome engineering platform spanning gene editing, base editing, epigenetic editing and transcriptional regulation. By delivering the genomic intervention each disease requires, Cellectis is advancing a new generation of genetic medicines designed to move beyond disease management and toward lasting therapeutic impact. Cellectis' headquarters are in Paris, France, with locations in New York and Raleigh (NC). Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker:ALCLS).
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- Europe
- Website
- cellectis.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.